Risperidone versus haloperidol in children and adolescents with AD: A randomized, controlled, double-blind trial

European Child and Adolescent Psychiatry

Volumn 17, Issue 1, 2008, Pages 1-8

  Miral, Suha ^a   Gencer, Ozlem ^a   Inal Emiroglu, F Neslihan ^a   Baykara, Burak ^a   Baykara, Aysen ^a   Dirik, Eray ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Autistic disorder; Haloperidol; Risperidone; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; HALOPERIDOL; PROLACTIN; RISPERIDONE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTISM; BEHAVIOR; BEHAVIOR DISORDER; BLUNTED AFFECT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GYNECOMASTIA; HUMAN; HUMAN RELATION; IMPULSIVENESS; INCREASED APPETITE; INSOMNIA; LABORATORY TEST; LANGUAGE; MALE; NOCTURIA; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RIGIDITY; SENSORIMOTOR FUNCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ALANINE TRANSAMINASE; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD BEHAVIOR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PERSONALITY ASSESSMENT; PROLACTIN; RISPERIDONE;

EID: 39149096262     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-007-0620-5     Document Type: Article

References (41)

1. Aman MG, Singh NN (1985) Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic 89:492-502
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). American Psychiatric Association, Washington DC
3. Anderson L, Campbell, M Adams P, Small AM, Perry R, Shell J (1989) The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227-239
4. Arnold LE, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, Cronin P, Koenig K, Kohn AE, McMahon DJ, Tierney E (2003) Parent defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 42(12):1443-1450
5. Barnard L, Young AH, Pearson C, Geddes J, O'Brien G (2003) A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 16(1):93-101
6. Buitelaar JK, Willemsen-Swinkels SHN (2000) Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 9:I/85-I/97
7. Campbell M, Geller B, Cohen IL (1977) Current status of drug research and treatment with autistic children. J Pediatr Psychol 4:153-161
8. Campbell M, Adams P, Perry R, Spencer EK, Overall JE (1988) Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 24:251-255
9. Campbell M, Schopler E, Cueva JE, Hallin A (1996) Treatment of AD. J Am Acad Child Adolesc Psychiatry 35:134-143
10. Campbell M, Armentos JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997) Neuroleptic- related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835-843
11. Campbell M, Rapoport JL, Simpson GM (1999) Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:537-545
12. Chouinard G, Ross-Chouinard A, Annable L (1980) Extrapyramidal symptom rating scale. Can J Neurol Sci 7:233
13. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT (1980) Behavioral effects of haloperidol in young autistic children: an objective analysis using a within-subjects reversal design. J Am Acad Child Adolesc Psychiatry 19:665-677
14. Findling RL, Maxwell K, Wiznitzer M (1997) An open clinical trial of risperidone monotherapy in young children with AD. Psychopharmacol Bull 33:155-159
15. Findling RL, McNamara NK (2004) Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 65(Suppl 6):30-44
16. Fisman S, Steele M (1996) Use of risperidone in PDDs: a case series. J Child Adolesc Psychopharmacol 6:177-190
17. Freeman BJ, Ritvo ER, Yokota A, Ritvo A (1986) A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Psychiatry 25:130-136
18. Gagliano A, Germano E, Pustorino G, Impallomeni C, D'Arrigo C, Calamoneri F, Spina E (2004) Risperidone treatment of children with AD: Effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39-47
19. Gillberg C (2000) Typical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 9:I/2-I/8
20. Guy W (1976) ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education and Welfare, Rockville, MD
21. Hellings JA, Zarcone JR, Crandall KI, Wallace D, Schraeder SR (2001) Weight gain in a controlled study of risperidone in children adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11:229-238
22. Lingjaerde O, Ahlfors UG, Bech P Dencker SJ Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand (suppl) 334:1-100
23. Locascio J, Malone R, Small A, Kafantaris V, Ernst M, Lynch NS, Overall JE, Campbell M (1991) Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 27:119-126
24. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140-147
25. Masi GM, Cosenza A, Mucci M (2001) Prolactin levels in young children with PDDs during risperidone treatment. J Child Adolesc Psychopharmacol 11:389-394
26. Masi GM, Cosenza A, Mucci M, Brovedani P (2001) Open trial of risperidone in 24 young children with PDDs. J Am Acad Child Adolesc Psychiatry 40:1206-1214
27. Masi GM, Cosenza A, Mucci M, Brovedani P (2003) A 3-year naturalistic study of preschool children with PDDs treated with risperidone. J Clin Psychiatry 64:1039-1047
28. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 5:314-321
29. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ (1997) Risperidone treatment of children and adolescents with PDDs: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693
30. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998) A double-blind, placebo controlled study of risperidone in adults with AD and the other PDDs. Arch Gen Psychiatry 55:633-641
31. McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGough JJ, Cronin P, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B, Volkmar FR, Votolato NA, Walson P (2000) Research Units on Pediatric Psychopharmacology (RUPP)-Autism Network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9:201-224
32. McDougle CJ, Scahill L, Aman MG, McCracken JT, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142-1148
33. Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372-376
34. Perry R, Campbell M, Adams P, Lynch N, Spencer EK, Curren EL, Overall JE. (1989) Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28:87-92
35. Remschmidt H, Hennighausen K, Clement HW, Heiser P, Schulz E (2000) Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 9:I/9-I/19
36. Scahill L, McCracken J, McDougle CJ, Aman M, Arnold LE, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey DJ, Swiezy N, Volkmar F, Ritz L, Vitiello B (2001) Methodological issues in designing a multisided trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 11:377-388
37. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other PDDs. Pediatrics 114:634-641
38. Turgay A (1993) Turgay PDDs scale. Copyright and publication: Integrative Therapy Institute, West Bloomfield, Michigan
39. Vasconcelos SM, Pereira RF, Alves RS Arruda Filho AC, Aguiar LM, Macedo DS, Freitas RM, Queiroz MG, Sousa FC, Viana GS (2004) Effects of ethanol and haloperidol on plasma levels of hepatic enzymes, lipid profile, and apolipoprotein in rats. Biochem Cell Biol 82(2):315-320
40. Volkmar FR, Klin A, Cohen DJ (1997) Diagnosis and classification of autism and related conditions. In: Volkmar FR, Cohen DJ (eds) Handbook of Autism and PDDs. New York, Wiley pp 5-40
41. Zuddas A, Di Martino A, Muglia P, Cianchetti C (2000) Long-term risperidone for PDD: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79-90